OR WAIT null SECS
Cytiva’s acquisition of CEVEC Pharmaceuticals strengthens the company’s cell line development and biomanufacturing capabilities.
Cytiva has acquired CEVEC Pharmaceuticals, a Germany-based provider of high-performance cell line development and viral vector manufacturing technologies, in a move that strengthens Cytiva's capabilities to offer biomanufacturing solutions.
With this acquisition, Cytiva gains CEVEC’s scalable producer cell lines for vectors based on adeno-associated virus and adenovirus, two widely used vectors for gene therapy delivery, according to an Oct. 6, 2022 company press release. Cytiva also gains producer cell lines (PCLs) enabled by CEVEC's ELEVECTA technology, which promotes yield, scalability, and robustness in the manufacturing process. The ELEVECTA technology provides all the components necessary for vector production integrated into the genome of the PCL, thus offering an alternative to technologies based on transfection or the use of a helper virus.
Under the agreement, CEVEC and its 46 scientific experts become part of Cytiva, effective immediately. CEVEC's products, services, and technologies will continue to carry the ELEVECTA and CAP brands in the immediate future and will be available to customers worldwide.
"[CEVEC's] innovative technology complements Cytiva's offering and brings the promise of improved viral vector manufacturing. With Cytiva's global reach and ability to scale, more customers will have access to [CEVEC's] technology and expertise to help accelerate and advance therapeutics for the benefit of patients," said Emmanuel Abate, president, Genomic Medicine at Cytiva, in the release.
"We are excited to become part of Cytiva. Combined with Cytiva's global presence and leading brands, this enables the whole gene therapy industry to embark on new and powerful solutions for scalable vector manufacturing and start a new era for therapies made available to patients in need," said Nicole Faust, CEO of CEVEC Pharmaceuticals, in the release.